Publikationen, an denen er mitarbeitet Oscar Briz Sánchez (11)

2024

  1. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

2021

  1. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

2020

  1. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression

    Hepatology, Vol. 72, Núm. 3, pp. 949-964

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2017

  1. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

2016

  1. Bile acids in physiology, pathology and pharmacology

    Current Drug Metabolism, Vol. 17, Núm. 1, pp. 4-29

  2. Mechanisms of resistance to chemotherapy in gastric cancer

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, Núm. 3, pp. 318-334

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102

2014

  1. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development

    Molecular Cancer Research, Vol. 12, Núm. 1, pp. 91-100

2013

  1. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

    Hepatology, Vol. 58, Núm. 3, pp. 1065-1073